• Je něco špatně v tomto záznamu ?

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia

H. Plešingerová, P. Janovská, A. Mishra, L. Smyčková, L. Poppová, A. Libra, K. Plevová, P. Ovesná, L. Radová, M. Doubek, Š. Pavlová, Š. Pospíšilová, V. Bryja,

. 2018 ; 103 (2) : 313-324. [pub] 20171109

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19013023

Grantová podpora
NV15-29793A MZ0 CEP - Centrální evidence projektů

Chronic lymphocytic leukemia is a disease with up-regulated expression of the transmembrane tyrosine-protein kinase ROR1, a member of the Wnt/planar cell polarity pathway. In this study, we identified COBLL1 as a novel interaction partner of ROR1. COBLL1 shows clear bimodal expression with high levels in chronic lymphocytic leukemia patients with mutated IGHV and approximately 30% of chronic lymphocytic leukemia patients with unmutated IGHV. In the remaining 70% of chronic lymphocytic leukemia patients with unmutated IGHV, COBLL1 expression is low. Importantly, chronic lymphocytic leukemia patients with unmutated IGHV and high COBLL1 have an unfavorable disease course with short overall survival and time to second treatment. COBLL1 serves as an independent molecular marker for overall survival in chronic lymphocytic leukemia patients with unmutated IGHV. In addition, chronic lymphocytic leukemia patients with unmutated IGHV and high COBLL1 show impaired motility and chemotaxis towards CCL19 and CXCL12 as well as enhanced B-cell receptor signaling pathway activation demonstrated by increased PLCγ2 and SYK phosphorylation after IgM stimulation. COBLL1 expression also changes during B-cell maturation in non-malignant secondary lymphoid tissue with a higher expression in germinal center B cells than naïve and memory B cells. Our data thus suggest COBLL1 involvement not only in chronic lymphocytic leukemia but also in B-cell development. In summary, we show that expression of COBLL1, encoding novel ROR1-binding partner, defines chronic lymphocytic leukemia subgroups with a distinct response to microenvironmental stimuli, and independently predicts survival of chronic lymphocytic leukemia with unmutated IGHV.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013023
003      
CZ-PrNML
005      
20201031182602.0
007      
ta
008      
190405s2018 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2017.178699 $2 doi
035    __
$a (PubMed)29122990
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Plešingerová, Hana $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine- Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
245    10
$a Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia / $c H. Plešingerová, P. Janovská, A. Mishra, L. Smyčková, L. Poppová, A. Libra, K. Plevová, P. Ovesná, L. Radová, M. Doubek, Š. Pavlová, Š. Pospíšilová, V. Bryja,
520    9_
$a Chronic lymphocytic leukemia is a disease with up-regulated expression of the transmembrane tyrosine-protein kinase ROR1, a member of the Wnt/planar cell polarity pathway. In this study, we identified COBLL1 as a novel interaction partner of ROR1. COBLL1 shows clear bimodal expression with high levels in chronic lymphocytic leukemia patients with mutated IGHV and approximately 30% of chronic lymphocytic leukemia patients with unmutated IGHV. In the remaining 70% of chronic lymphocytic leukemia patients with unmutated IGHV, COBLL1 expression is low. Importantly, chronic lymphocytic leukemia patients with unmutated IGHV and high COBLL1 have an unfavorable disease course with short overall survival and time to second treatment. COBLL1 serves as an independent molecular marker for overall survival in chronic lymphocytic leukemia patients with unmutated IGHV. In addition, chronic lymphocytic leukemia patients with unmutated IGHV and high COBLL1 show impaired motility and chemotaxis towards CCL19 and CXCL12 as well as enhanced B-cell receptor signaling pathway activation demonstrated by increased PLCγ2 and SYK phosphorylation after IgM stimulation. COBLL1 expression also changes during B-cell maturation in non-malignant secondary lymphoid tissue with a higher expression in germinal center B cells than naïve and memory B cells. Our data thus suggest COBLL1 involvement not only in chronic lymphocytic leukemia but also in B-cell development. In summary, we show that expression of COBLL1, encoding novel ROR1-binding partner, defines chronic lymphocytic leukemia subgroups with a distinct response to microenvironmental stimuli, and independently predicts survival of chronic lymphocytic leukemia with unmutated IGHV.
650    _2
$a pohyb buněk $7 D002465
650    _2
$a polarita buněk $7 D016764
650    _2
$a lidé $7 D006801
650    _2
$a těžké řetězce imunoglobulinů $x genetika $7 D007143
650    _2
$a variabilní oblast imunoglobulinu $x genetika $7 D007135
650    _2
$a chronická lymfatická leukemie $x klasifikace $x diagnóza $x genetika $x mortalita $7 D015451
650    _2
$a mutace $7 D009154
650    _2
$a prognóza $7 D011379
650    _2
$a vazba proteinů $7 D011485
650    _2
$a sirotčí receptory podobné receptoru tyrosinkinasy $x metabolismus $7 D057050
650    _2
$a analýza přežití $7 D016019
650    _2
$a transkripční faktory $x metabolismus $7 D014157
650    _2
$a signální dráha Wnt $7 D060449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Janovská, Pavlína $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic.
700    1_
$a Mishra, Archana $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Smyčková, Lucie $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Poppová, Lucie $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine- Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Libra, Antonín $u Generi Biotech, s.r.o., Hradec Králové, Brno, Czech Republic.
700    1_
$a Plevová, Karla $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine- Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Ovesná, Petra $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
700    1_
$a Radová, Lenka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Doubek, Michael $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine- Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Pavlová, Šárka $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine- Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Pospíšilová, Šárka $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine- Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Bryja, Vítězslav $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic bryja@sci.muni.cz. Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 103, č. 2 (2018), s. 313-324
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29122990 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20201031182602 $b ABA008
999    __
$a ok $b bmc $g 1392333 $s 1051328
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 103 $c 2 $d 313-324 $e 20171109 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a NV15-29793A $p MZ0
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace